Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT02716805
Title Phase 1 Study to Assess Safety & Tolerability of Tremelimumab & Durvalumab, Administered With High Dose Chemotherapy and Autologous Stem Cell Transplant
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors Ludwig Institute for Cancer Research
Age Groups: adult
Covered Countries USA

No variant requirements are available.